Investigational drug · Phase 2
VV913
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Premature Ejaculation.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "VV913"
First trial start
2026
Aug 31, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VV913", any sponsor or status.
Conditions studied
As listed on its trial records.
- Premature Ejaculation
Largest trials
Live from ClinicalTrials.gov: studies naming "VV913" as an intervention, largest first.
- Evaluate the Efficacy and Safety of VV913 Capsules in the Treatment of PEPivotal-lookingNot yet recruiting
Vigonvita Life SciencesIndustry
NCT07722780 · 500 participants (planned) · Start Aug 31, 2026 · Primary completion Dec 31, 2027
Drug: VV913 2mg Capsules; VV913 5mg Capsules and 2 more · For: Premature Ejaculation
Sites: Beijing, China
Vigonvita Life SciencesIndustry
NCT07372703 · 56 participants (planned) · Start Jan 29, 2026 · Primary completion Sep 2026
Drug: VV913 1mg group; VV913 2mg group and 5 more · For: Healthy Volunteers
Sites: Hefei, China
Vigonvita Life SciencesIndustry
NCT07507838 · 24 participants (planned) · Start Apr 13, 2026 · Primary completion Dec 31, 2026
Drug: VV913 4mg group; VV913 8mg group and 1 more · For: Healthy Volunteers
Sites: Hefei, China
Vigonvita Life SciencesIndustry
NCT07565792 · 12 participants (planned) · Start May 11, 2026 · Primary completion Dec 31, 2026
Drug: VV913; VV913 and 1 more · For: Healthy Volunteers
Sites: Hefei, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Premature Ejaculation
- KH-001Phase 22 trials
Kadence Bio · Premature Ejaculation, Dentin Hypersensitivity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.